Beta
SABA
albuterol
beta‐2
levalbuterol
pharmacokinetics
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
16 Aug 2024
16 Aug 2024
Historique:
revised:
19
07
2024
received:
27
03
2024
accepted:
01
08
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
aheadofprint
Résumé
Salbutamol is a common short-acting beta
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Danish Ministry of Culture (Sports Science)
Organisme : Anti Doping Danmark
Informations de copyright
© 2024 The Author(s). Drug Testing and Analysis published by John Wiley & Sons Ltd.
Références
World Anti‐Doping Agency. Minutes of the WADA Executive Committee Meeting 20 September 2018. https://www.wada-ama.org/sites/default/files/resources/files/executive_committee_meeting_minutes_20092018.pdf. Accessed 1 October 2019.
Moore A, Riddell K, Joshi S, Chan R, Mehta R. Pharmacokinetics of salbutamol delivered from the unit dose dry powder inhaler: comparison with the metered dose inhaler and Diskus dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2017;30(3):164‐172. doi:10.1089/jamp.2015.1277
Milano G, Chiappini S, Mattioli F, Martelli A, Schifano F. β‐2 agonists as misusing drugs? Assessment of both clenbuterol‐ and salbutamol‐related European Medicines Agency Pharmacovigilance Database Reports. Basic Clin Pharmacol Toxicol. 2018;123(2):182‐187. doi:10.1111/bcpt.12991
Phillips PJ, Vedig AE, Jones PL, et al. Metabolic and cardiovascular side effects of the beta 2‐adrenoceptor agonists salbutamol and rimiterol. Br J Clin Pharmacol. 1980;9(5):483‐491. doi:10.1111/j.1365‐2125.1980.tb05844.x
Lipworth BJ, Brown RA, McDevitt DG. Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2‐adrenoceptor blockade. Br J Clin Pharmacol. 1989;28(1):95‐102. doi:10.1111/j.1365‐2125.1989.tb03510.x
Lipworth BJ, McDevitt DG, Struthers AD. Systemic beta‐adrenoceptor responses to salbutamol given by metered‐dose inhaler alone and with pear shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects. Br J Clin Pharmacol. 1989;27(6):837‐842. doi:10.1111/j.1365‐2125.1989.tb03447.x
Hostrup M, Kalsen A, Ortenblad N, et al. beta2‐adrenergic stimulation enhances Ca2+ release and contractile properties of skeletal muscles, and counteracts exercise‐induced reductions in Na+‐K+‐ATPase Vmax in trained men. J Physiol. 2014;592(Pt 24):5445‐5459. doi:10.1113/jphysiol.2014.277095
Hostrup M, Kalsen A, Bangsbo J, Hemmersbach P, Karlsson S, Backer V. High‐dose inhaled terbutaline increases muscle strength and enhances maximal sprint performance in trained men. Eur J Appl Physiol. 2014;114(12):2499‐2508. doi:10.1007/s00421‐014‐2970‐2
Kalsen A, Hostrup M, Soderlund K, Karlsson S, Backer V, Bangsbo J. Inhaled beta2‐agonist increases power output and glycolysis during sprinting in men. Med Sci Sports Exerc. 2016;48(1):39‐48. doi:10.1249/MSS.0000000000000732
Jessen S, Onslev J, Lemminger A, Backer V, Bangsbo J, Hostrup M. Hypertrophic effect of inhaled beta2 ‐agonist with and without concurrent exercise training: a randomized controlled trial. Scand J Med Sci Sports. 2018;28(10):2114‐2122. doi:10.1111/sms.13221
Onslev J, Jacobson G, Narkowicz C, et al. Beta2‐adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight men. Eur J Appl Physiol. 2017;117(9):1907‐1915. doi:10.1007/s00421‐017‐3679‐9
Williams RS, Caron MG, Daniel K. Skeletal muscle beta‐adrenergic receptors: variations due to fiber type and training. Am J Physiol. 1984;246(2 Pt 1):E160‐E167. doi:10.1152/ajpendo.1984.246.2.E160
Jensen J, Brennesvik EO, Bergersen H, Oseland H, Jebens E, Brors O. Quantitative determination of cell surface beta‐adrenoceptors in different rat skeletal muscles. Pflugers Arch. 2002;444(1–2):213‐219. doi:10.1007/s00424‐002‐0793‐1
Joassard OR, Durieux AC, Freyssenet DG. beta2‐Adrenergic agonists and the treatment of skeletal muscle wasting disorders. Int J Biochem Cell Biol. 2013;45(10):2309‐2321. doi:10.1016/j.biocel.2013.06.025
Hostrup M, Kalsen A, Onslev J, et al. Mechanisms underlying enhancements in muscle force and power output during maximal cycle ergometer exercise induced by chronic beta2‐adrenergic stimulation in men. J Appl Physiol (1985). 2015;119(5):475‐486. doi:10.1152/japplphysiol.00319.2015
Lemminger AK, Jessen S, Habib S, et al. Effect of beta2 ‐adrenergic agonist and resistance training on maximal oxygen uptake and muscle oxidative enzymes in men. Scand J Med Sci Sports. 2019;29(12):1881‐1891. doi:10.1111/sms.13544
Hostrup M, Reitelseder S, Jessen S, et al. Beta2 ‐adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men. J Physiol. 2018;596(17):4121‐4139. doi:10.1113/JP275560
Caruso JF, Hamill JL, Yamauchi M, et al. Albuterol helps resistance exercise attenuate unloading‐induced knee extensor losses. Aviat Space Environ Med. 2004;75(6):505‐511.
Caruso JF, Hamill JL, De Garmo N. Oral albuterol dosing during the latter stages of a resistance exercise program. J Strength Cond Res. 2005;19(1):102‐107.
Hostrup M, Kalsen A, Auchenberg M, Bangsbo J, Backer V. Effects of acute and 2‐week administration of oral salbutamol on exercise performance and muscle strength in athletes. Scand J Med Sci Sports. 2016;26(1):8‐16. doi:10.1111/sms.12298
Martineau L, Horan MA, Rothwell NJ, Little RA. Salbutamol, a beta 2‐adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci (Lond). 1992;83(5):615‐621. doi:10.1042/cs0830615
Ward JK, Dow J, Dallow N, Eynott P, Milleri S, Ventresca GP. Enantiomeric disposition of inhaled, intravenous and oral racemic‐salbutamol in man — no evidence of enantioselective lung metabolism. Br J Clin Pharmacol. 2000;49(1):15‐22. doi:10.1046/j.1365‐2125.2000.00102.x
Boulton DW, Fawcett JP. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol. 1996;41(1):35‐40. doi:10.1111/j.1365‐2125.1996.tb00156.x
Boulton DW, Fawcett JP. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Clin Pharmacol Ther. 1997;62(2):138‐144. doi:10.1016/S0009‐9236(97)90061‐8
Jacobson GA, Fawcett JP. Beta2‐agonist doping control and optical isomer challenges. Sports Med. 2016;46(12):1787‐1795. doi:10.1007/s40279‐016‐0547‐4
Jacobson GA, Hostrup M, Narkowicz CK, Nichols DS, Walters EH. Enantioselective disposition of (R,R)‐formoterol, (S,S)‐formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control. Drug Test Anal. 2019;11(7):950‐956. doi:10.1002/dta.2587
Jacobson GA, Raidal S, Robson K, Narkowicz CK, Nichols DS, Walters EH. Salmeterol undergoes enantioselective bronchopulmonary distribution with receptor localisation a likely determinant of duration of action. J Pharm Biomed Anal. 2018;154:102‐107. doi:10.1016/j.jpba.2018.02.048
Jacobson GA, Raidal S, Hostrup M, et al. Long‐acting beta2‐agonists in asthma: enantioselective safety studies are needed. Drug Saf. 2018;41(5):441‐449. doi:10.1007/s40264‐017‐0631‐1
Jacobson GA, Raidal S, Robson K, Narkowicz CK, Nichols DS, Haydn WE. Bronchopulmonary pharmacokinetics of (R)‐salbutamol and (S)‐salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses. Br J Clin Pharmacol. 2017;83(7):1436‐1445. doi:10.1111/bcp.13228
Jacobson GA, Hostrup M, Narkowicz CK, Nichols DS, Haydn WE. Enantioselective disposition of (R)‐salmeterol and (S)‐salmeterol in urine following inhaled dosing and application to doping control. Drug Test Anal. 2017;9(8):1262‐1266. doi:10.1002/dta.2131
Jacobson GA, Yee KC, Wood‐Baker R, Walters EH. SULT 1A3 single‐nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? Drug Test Anal. 2015;7(2):109‐113. doi:10.1002/dta.1645
Jacobson GA, Chong FV, Wood‐Baker R. (R,S)‐Salbutamol plasma concentrations in severe asthma. J Clin Pharm Ther. 2003;28(3):235‐238. doi:10.1046/j.1365‐2710.2003.00483.x
Zhang M, Fawcett JP, Shaw JP. Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. Br J Clin Pharmacol. 2002;54(3):246‐250. doi:10.1046/j.1365‐2125.2002.01641.x
Jacobson GA, Yee KC, Premilovac D, Rattigan S. Enantioselective disposition of (R/S)‐albuterol in skeletal and cardiac muscle. Drug Test Anal. 2014;6(6):563‐567. doi:10.1002/dta.1575
Hostrup M, Narkowicz CK, Habib S, Nichols DS, Jacobson GA. Beta2 ‐adrenergic ligand racemic formoterol exhibits enantioselective disposition in blood and skeletal muscle of humans, and elicits myocellular PKA signaling at therapeutic inhaled doses. Drug Test Anal. 2019;11(7):1048‐1056. doi:10.1002/dta.2580
Murphy RJ, Hartkopp A, Gardiner PF, Kjaer M, Beliveau L. Salbutamol effect in spinal cord injured individuals undergoing functional electrical stimulation training. Arch Phys Med Rehabil. 1999;80(10):1264‐1267. doi:10.1016/S0003‐9993(99)90027‐8
Martineau L, Horan MA, Rothwell NJ, Little RA. Muscling in on salbutamol. Lancet. 1992;340(8827):1094. doi:10.1016/0140‐6736(92)93110‐9
Skura CL, Fowler EG, Wetzel GT, Graves M, Spencer MJ. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology. 2008;70(2):137‐143. doi:10.1212/01.WNL.0000287070.00149.a9
Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest. 1975;35(7):609‐616. doi:10.3109/00365517509095787
Jessen S, Lemminger A, Backer V, et al. Inhaled formoterol impairs aerobic exercise capacity in endurance‐trained individuals: a randomised controlled trial. ERJ Open Res. 2023;9(2):00643‐02022. doi:10.1183/23120541.00643‐2022
Ryall JG, Gregorevic P, Plant DR, Sillence MN, Lynch GS. Beta 2‐agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am J Physiol Regul Integr Comp Physiol. 2002;283(6):R1386‐R1394. doi:10.1152/ajpregu.00324.2002